Skip to content
value.today

Juventas Therapeutics Inc.

🇺🇸 Cleveland, Ohio, USABiotechnologyFounded 2007
Total raised
$34 M
3 rounds on record
Latest round
$7 M
May 2015
First round on record
Sep 2008
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Juventas Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2015$7 MNo. 3$2 to $10 million

Juventas Therapeutics Inc.: Raise no. 3, May 2015

Investors in this round

37 investors had bought by the notice of May 19, 2015: 37 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Marc Penn · Executive Officer, Director
  • Rahul Aras · Executive Officer, Director
  • Troy Ignelzi · Executive Officer
  • George Arida · Director
  • James Boland · Director
  • Linda Tufts · Director
  • Matthew Pollman · Director
  • Roger Newton · Director
  • Somu Subramaniam · Director
  • Suzette Dutch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Rahul Aras, Ceo. Source: SEC Form D, newest notice filed May 19, 2015. Read the notice at the SEC.

equitySEC
Oct 2013$5 MNo. 2$2 to $10 million

Juventas Therapeutics Inc.: Raise no. 2, Oct 2013

Investors in this round

45 investors had bought by the notice of Nov 20, 2013: 45 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Shares of preferred stock with warrants to purchase additional shares of preferred stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rahul Aras · Executive Officer, Director
  • George Arida · Director
  • Linda Tufts · Director
  • Marc Penn · Director
  • Matthew Pollman · Director
  • Roger Newton · Director
  • Somu Subramaniam · Director
  • Suzette Dutch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Rahul Aras, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 20, 2013. Read the notice at the SEC.

equity, optionsSEC
Sep 2008$22 MNo. 1$10 to $50 million

Juventas Therapeutics Inc.: Raise no. 1, Sep 2008

Investors in this round

35 investors had bought by the notice of Aug 8, 2012: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rahul Aras · Executive Officer, Director
  • George Arida · Director
  • George Emont · Director
  • Linda Tufts · Director
  • Marc Penn · Director
  • Matt Pollman · Director
  • Roger Newton · Director
  • Somu Subramaniam · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Rahul Aras, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 8, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Juventas Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (May 2015).

    SEC Form D · May 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2015

That is all the official record says: Juventas Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Juventas Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 45 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Juventas Therapeutics Inc.
NameRoleNamed in
Marc PennExecutive officerMay 2015
Rahul ArasExecutive officerMay 2015
Troy IgnelziExecutive officerMay 2015
George AridaDirectorMay 2015
James BolandDirectorMay 2015
Linda TuftsDirectorMay 2015
Marc PennDirectorMay 2015
Matthew PollmanDirectorMay 2015
Rahul ArasDirectorMay 2015
Roger NewtonDirectorMay 2015
Somu SubramaniamDirectorMay 2015
Suzette DutchDirectorMay 2015
George EmontDirectorAug 2012
Matt PollmanDirectorAug 2012